|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.005 - 0.006|
|52 Week Range||0.005 - 0.030|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly bioavailable extracts, today announced that its affiliate company, Protext Pharma, Inc. (TXTM), held a meeting July 4th 2018 at the company’s office in White River, Mpumalanga, with senior Government staff members of the South African Health Products Regulatory Authority (SAHPRA) (formerly known as the Medicine Control Council-MCC). The meetings included in-depth discussion of the company’s anticipated medical cannabis business in the country, site visit and complete inspection of a large industrial building the company has secured and plans to use for growing, cultivating and extraction of cannabis for medical research and development purposes. The completion of the facility site inspection is a big milestone in the process of pursuing this government issued license, and is believed to be the final hurdle before Protext and one of its subsidiaries is issued one of the first licenses in South Africa that will allow for establishing a research and development platform for developing cannabis based medicines.
The United States has the largest broiler chicken industry in the world with about 16.5 percent of production exported to other countries in 2017. In 2017, almost 9 billion broiler chickens, weighing over 55 billion pounds liveweight, were produced.
Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed its focus on developing the international nutraceutical market for its full-profile, non-psychoactive cannabis extract. The international market for nutraceutical or wellness products is expected to reach $302,306 million by 2022 from $184,092 million in 2015, with an annual growth rate of 7.04% from 2016 to 2022. Recent innovations and findings of function-specific antioxidants are expected to create new opportunities in the international sector, and the Company believes its highly bioavailable, full-profile, non-psychoactive cannabis extract will play a role in this emerging growth market.
Vision is to Produce World’ s Only Full-Profile Non-Psychoactive Cannabis Extract. LONDON, UNITED KINGDOM, June 14, 2018-- Plandaí Biotechnology, Inc., producer of the highly bioavailable Phytofare ® catechin ...
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed the potential benefits of using highly-bioavailable green tea catechins, like those found in the Company’s proprietary Phytofare® extract, in treating people suffering from Type II diabetes. Worldwide as of 2013, 382 million people, or 8.3% of the adult population, have diabetes, with Type II Diabetes making up about 90% of the cases. In 2014, the International Diabetes Federation estimated that diabetes resulted in 4.9 million annual deaths. Callum Cottrell-Duffield, Chief Operating Officer of Plandai, commented, “Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to report positive results from chicken studies on how Phytofare® infused SORBEO™ is beneficial as a feed additive in poultry diets. The studies examined the benefits of Phytofare® when delivered in a low dosage formulated in liposome iotas, then added to feed formulations which were fed to the control groups of chickens.
Natural & Organic Products Europe is Europe’s biggest trade show for natural & organic products, making it the ‘must attend’ event for buyers of natural health and living products, natural and organic food & drink as well as natural beauty & personal care products. Awards are given out annually highlighting the very best products, individuals and stores throughout the continent.
Based on the results of published studies, the addition of generic green tea catechins to the diets of both broilers and layers has been shown to improve the productive performance and reduce the cholesterol content in the serum and egg yolk, implying its potential effect on egg-quality parameters. Furthermore, the addition of generic green tea catechins in the chickens’ diet decreases all microflora counts in the caecum due to an antibiotic-like effect. In this review, it was found that green tea catechins’ inclusion in broiler diets had positive effects on growth performance and lean meat production, whereas catechins in high dosage tended to decrease feed intake and body weight gain but delivered an improved feed conversion ratio.
Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide background on the current known issues in the global poultry industry and its identification of potential opportunities. Globally, more than 58 billion chickens are raised annually as a source of food, for both their meat and eggs. Chicken producers use nationally approved medications, such as antibiotics and antivirals in feed or drinking water, to treat disease or to prevent disease outbreaks. As a result of the ban on the use of antibiotic growth promoters in animal diets in the European Union as from January 2006, and the growing pressure on poultry producers in other parts of the world, alternative substances and strategies for animal health and growth promotion are now necessary.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update on its successful roll-out of its Phytofare® supplement. Plandaí Biotech’s Phytofare®, is the only clinically proven green tea extract shown to be bioavailable. Generic green tea extracts are thought to have bioavailability of between 1-10% whereas Phytofare® has shown in a human bioavailability study to have a bioavailability of 10 times that of generic green tea extract.
Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to provide an update to its Phytofare solution as a preventive mitigation against Type 2 diabetes. In looking for a natural solution, epidemiological studies indicate that populations with a high intake of green tea catechins benefit in terms of reduced body weight, body fat, the balance of insulin and glucagon, maintaining blood glucose, and cardiovascular health.
Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to discuss green tea and its positive natural attributes in helping to prevent and fight Type 2 diabetes. Generally, diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar.
Company History in Cannabis Research Dates Back to February 2013. LONDON, UNITED KINGDOM, April 25, 2018-- Plandai Biotechnology Inc., a producer of nutraceutical and highly phyto-available extracts, today ...